4.7 Article

ASPP1 deficiency promotes epithelial-mesenchymal transition, invasion and metastasis in colorectal cancer

Journal

CELL DEATH & DISEASE
Volume 11, Issue 4, Pages -

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41419-020-2415-2

Keywords

-

Categories

Funding

  1. National Natural Science Foundation of China [81772827]
  2. Academy of Medical Sciences/the Wellcome Trust Springboard Award [SBF002\1038]
  3. Medical Research Council [MR/S025480/1]
  4. Wessex Medical Trust
  5. Gerald Kerkut Charitable Trust
  6. University of Southampton Central VC Scholarship Scheme
  7. Institute for Life Sciences PhD Studentship
  8. Natural Science Foundation of Hubei Province [2018CFB611]
  9. Ludwig Institute for Cancer Research Ltd
  10. National Institute for Health Research (NIHR) Oxford Biomedical Research Centre (BRC)
  11. MRC [MR/S025480/1] Funding Source: UKRI

Ask authors/readers for more resources

The apoptosis-stimulating protein of p53 (ASPP) family of proteins can regulate apoptosis by interacting with the p53 family and have been identified to play an important role in cancer progression. Previously, we have demonstrated that ASPP2 downregulation can promote invasion and migration by controlling beta-catenin-dependent regulation of ZEB1, however, the role of ASPP1 in colorectal cancer (CRC) remains unclear. We analyzed data from The Cancer Genome Atlas (TCGA) and coupled this to in vitro experiments in CRC cell lines as well as to experimental pulmonary metastasis in vivo. Tissue microarrays of CRC patients with information of clinical-pathological parameters were also used to investigate the expression and function of ASPP1 in CRC. Here, we report that loss of ASPP1 is capable of enhancing migration and invasion in CRC, both in vivo and in vitro. We demonstrate that depletion of ASPP1 could activate expression of Snail2 via the NF-kappa B pathway and in turn, induce EMT; and this process is further exacerbated in RAS-mutated CRC. ASPP1 could be a prognostic factor in CRC, and the use of NF-kappa B inhibitors may provide new strategies for therapy against metastasis in ASPP1-depleted CRC patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available